Boston—A Cochrane review of clinical trials with the new generation of drugs to treat hepatitis C infection has concluded no evidence exists yet that the drugs improve outcomes in patients infected with the virus.
The review, by researchers in Denmark, associated direct-acting antiviral (DAA) agents with an increased likelihood of sustained viral response (SVR), which has been the primary end point of most randomized clinical trials. But the authors argue that SVR is a surrogate outcome